News

16/04/2014 12:04
  The Vall d'Hebron Institute of Research (VHIR) and the biopharmaceutical SOM Biotech, based at the Barcelona Science Park (PCB), have signed an agreement to jointly develop the clinical phase of a drug for transthyretin Amyloidosis (ATTR). The collaboration starts...
<< 1 | 2